Eric Lefkofsky started the company Tempus to deliver artificial intelligence to doctors and researchers, focusing on precision medicine. The company’s intention is to help physicians acclimate to new ways of working in their focus field of cancer. Not only did Tempus’ launch succeed in its endeavor, but they also expanded into cardiology and depression as well as into infectious diseases, starting with Covid-19 (Patch).
The company started as a means for doctors to help them interpret genomic information and make decisions in real-time; the technology is now growing into bio-pharma. The company has partnerships with J&J, ASCO and Janssen. Led by Eric Lefkofsky, Tempus recently announced its newest cloud-based data and analytics platform, Lens. The platform is an all-in-one on-demand access to molecular and clinical datasets for researchers and scientists while also giving them AI access to help advance new drug exploration and advancement.
Eric Lefkofsky’s Tempus has raised more than $200 million from investors. These investors of all kinds include Google, managed funds by T. Rowe Price, Nove Holdings, Franklin Templeton, and Baillie Gifford. Lefkofsky also invested $100+ million of his own money to reach Tempus’ goal of bringing AI medicine to help new diseases. The company also wants to use the raised funds to expand the company and hire more employees. They have added 700 employees since the start of the pandemic, to add to their already 1,800.